A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma

drug protocol number
AGB 002
drug sponsor
Archigen Biotech Limited
drug study
Rituximab / SAIT101
drug trial site
PSMMC
drug status
Completed
drug phase